3-FMA
3-fluoro-N-methylamphetamine
Viewing r1 — May 7, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
3-FMA (3-fluoromethamphetamine) is a synthetic stimulant of the phenethylamine class. It is a fluorinated structural analog of methamphetamine, distinguished by a shorter duration and less intense euphoria. 3-FMA is a monoamine releasing agent, producing its effects by flooding synapses with dopamine, norepinephrine, and serotonin.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
amphetamine, methamphetamine, MDMA +1 moreamphetamine, methamphetamine, MDMA, other monoamine releasing agents show less
3-FMA emerged on research chemical markets in the late 2000s as one of several fluorinated amphetamine analogs designed to circumvent methamphetamine scheduling.[2] It first appeared in Finnish regulatory notifications around 2009 and subsequently spread to global online vendors. It remains unscheduled in the United States but is controlled in Canada, China, Germany, and the United Kingdom.
Subjective effects include cognitive stimulation, physical stimulation, euphoria, enhanced sociability, and increased motivation. The experience is described as clean and task-oriented — a functional stimulant profile closer to focused productivity than to the empathogenic warmth of its para-substituted isomer 4-FMA.[3] Post-stimulant dysphoria, insomnia, irritability, and compulsive redosing urges are common unsought effects.
Rodent data indicate high abuse liability comparable to methamphetamine,[4] with dose-dependent neurotoxicity driven by D1 receptor activation, hyperthermia, and oxidative stress.[5] Human fatalities have been reported to regulatory bodies in Finland and England/Wales, though no peer-reviewed case reports document the circumstances or doses.[6] No controlled human studies have been conducted — the evidence base rests on rodent pharmacology and community reports.
History[edit]
Discovery
No single researcher or synthesis date has been documented for 3-FMA. It belongs to a family of fluorinated amphetamine analogs — including 2-FMA, 4-FA, and 4-FMA — that emerged on research chemical markets in the late 2000s as structural variants designed to fall outside methamphetamine scheduling. The earliest regulatory detection occurred in Finland around 2009, followed by a United States notification around 2011.[2]
Research trajectory
Published research on 3-FMA began in 2018 with a neurotoxicity study in mice,[5] followed by characterization of its rewarding and reinforcing properties in rodents in 2020.[4] Comparative locomotor and discriminative stimulus data for all fluoromethamphetamine positional isomers were published in 2025.[6] No clinical research has been conducted in humans, and 3-FMA has no documented therapeutic application.
Prohibition
Scheduling actions followed the typical pattern for novel psychoactive stimulants. Canada controlled 3-FMA under Schedule I as a methamphetamine analog, China added it in October 2015, and Germany captured it under the Neue-psychoaktive-Stoffe-Gesetz in November 2016.[2] The United Kingdom's Psychoactive Substances Act 2016 implemented a blanket prohibition on novel psychoactive substance supply and production.
The name follows standard research chemical nomenclature: the number indicates ring substitution position, "F" denotes fluorine, and "MA" abbreviates methamphetamine. Among its positional isomers, 3-FMA occupies an intermediate reputation — less studied than 2-FMA (widely discussed as a functional stimulant) and less popular than 4-FMA (known for its empathogenic character). Community discussion tends to characterize it as the overlooked middle member of the fluoromethamphetamine series.
Chemistry[edit]
Structural class
3-FMA (IUPAC: 1-(3-fluorophenyl)-N-methylpropan-2-amine) is a substituted amphetamine built on the methamphetamine scaffold. A fluorine atom replaces a hydrogen at the meta (3) position of the phenyl ring, placing it alongside 2-FMA (ortho) and 4-FMA (para) in the fluorinated methamphetamine series.
Fluorine substitution affects pharmacology through several mechanisms: its high electronegativity alters electron density across the ring, the carbon–fluorine bond resists metabolic oxidation at the substituted position, and fluorine's small atomic radius minimizes steric disruption compared to chlorine or bromine. Meta-positioned fluorine produces a more dopamine- and norepinephrine-dominant profile compared to para-substitution, which consistently enhances serotonergic activity in phenethylamines.[3]
Molecular properties
| Molecular formula | C₁₀H₁₄FN |
| Molecular weight | 167.22 g/mol (free base) |
Stereochemistry
3-FMA contains a single chirality center at the alpha carbon, generating R and S enantiomers. Research chemical samples are typically encountered as the racemic mixture. No studies comparing the pharmacological activity of individual 3-FMA enantiomers have been published.
By analogy with methamphetamine — where the S-(+) enantiomer is substantially more potent as a stimulant — stereoselective differences in potency are expected but uncharacterized.citation needed
Physical properties
No published characterization of the melting point, solubility, or stability profile of 3-FMA exists in the peer-reviewed literature. The hydrochloride salt is commercially available as a forensic reference standard.[7]
The ring fluorine is metabolically stable under normal physiological conditions, based on data from the structurally analogous 2-FMA.[8]
Pharmacology[edit]
Mechanism of action
3-FMA enters presynaptic nerve terminals through the same transporters that normally recycle dopamine, norepinephrine, and serotonin. Once inside, it displaces these neurotransmitters from their storage vesicles and forces them back out into the synapse through the transporters running in reverse.[1]
This mechanism has been confirmed in rodent studies showing depleted dopamine stores, reduced transporter expression, and increased dopamine turnover in the striatum following 3-FMA administration.[5] A notable distinction from methamphetamine emerged from this work: 3-FMA's neurotoxicity depends on D1 dopamine receptor activation rather than D2, suggesting differences in downstream signaling despite the shared releasing mechanism.[5]
No binding affinity data exist for 3-FMA at any transporter. Its profile is inferred from positional isomer comparisons — meta-substitution predicts stronger dopamine and norepinephrine release relative to serotonin, making 3-FMA more catecholamine-dominant than its para-substituted isomer 4-FMA.[3]
Pharmacokinetics
No human pharmacokinetic studies have been published for 3-FMA. Community harm reduction databases report oral onset within 20–60 minutes, peak effects at 2–4 hours, and total duration of 3–7 hours with aftereffects persisting 6–12 hours.[9][10]
Metabolism likely proceeds through the same liver enzyme pathways as methamphetamine. The ring fluorine blocks one common metabolic route at its position, redirecting breakdown through alternative pathways. Data from the structurally analogous 2-FMA confirm that the ring fluorine is stable and does not detach during normal metabolism.[8]
CYP2D6 poor metabolizer status — present in approximately 5–10% of Caucasian populations — may increase exposure and toxicity risk, based on analogy with the related compound PMMA, where poor metabolizers showed significantly elevated drug levels.[11][12]
Neuroscience[edit]
Reward circuitry
3-FMA strongly activates the brain's reward system — the dopamine pathway running from the ventral tegmental area to the nucleus accumbens. Rodent studies demonstrate robust conditioned place preference and high-effort self-administration behavior, confirming that 3-FMA generates both hedonic pleasure and motivational drive to seek the drug.[4]
Cross-reinstatement by both methamphetamine and cocaine priming indicates convergent activation of the same reward circuitry underlying established stimulant addiction.[4]
Striatal neurotoxicity
At high doses, 3-FMA overwhelms the striatum's antioxidant defenses, triggering a neurotoxic cascade: massive dopamine release generates reactive oxygen species, microglia shift to an inflammatory state, and nerve cells begin dying.[5] This damage is comparable in magnitude to equimolar methamphetamine but operates through D1 rather than D2 receptor activation — a distinction that may mean conventional antipsychotic drugs (D2 blockers) would not protect against 3-FMA-induced brain damage.[5]
Several fundamental questions remain unanswered. No in vitro data exist to quantify 3-FMA's relative potency at dopamine versus serotonin transporters — the single measurement that would definitively classify its pharmacological profile. Whether the D1-dependent neurotoxicity mechanism observed in rodents translates to humans is unknown, and the neurotoxicity threshold for chronic low-dose exposure — the pattern most relevant to human use — has never been studied in any species.
Subjective Effects[edit]
The 3-FMA experience centers on functional stimulation — cognitive sharpening, physical energy, and heightened motivation without the empathogenic warmth associated with more serotonergic compounds. At lower doses, structured environments channel the stimulation toward productive focus; at higher doses, euphoria and sociability become more prominent, though at the cost of a more punishing offset phase marked by dysphoria, fatigue, and irritability.
Pharmacologically, 3-FMA sits closer to methamphetamine than to MDMA on the stimulant–entactogen spectrum. Its interoceptive cues are indistinguishable from methamphetamine in trained rodents, but community sources describe the subjective experience as less intense and less euphoric than methamphetamine at comparable doses, with 4-FMA occupying the more serotonergic, empathogenic space in the fluoromethamphetamine family.
Effect Grid
A clear functional stimulant state — sustained focus enhancement, physical energy, cognitive euphoria, and sociability enhancement are all prominent. Thought acceleration is noticeable, with ideas flowing quickly and task engagement heightened. Motivation enhancement makes sustained work feel natural.
Appetite suppression is pronounced and may persist well into the aftereffects phase. Bruxism, excessive sweating, and mild cardiovascular activation (elevated heart rate, slight vasoconstriction) become noticeable. Dehydration sensation increases. The compulsive redosing urge may emerge at this level and should be anticipated.
The aftereffects phase (6–12 hours) is disproportionately long relative to the 2–4 hour peak. Post-stimulant irritability, depressed mood, and cognitive fatigue are common. Sleep disruption extends well beyond subjective offset — evening dosing should be avoided.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual processing acceleration
Dry mouth · Insomnia · Physical fatigue · Pupil dilation · Dehydration sensation · Heart rate perception changes · Muscle tension · Restlessness · Excessive sweating · Body high · Headache · Respiratory stimulation · Sexual arousal enhancement · Bruxism · Tactile euphoria · Breathing alteration · Nausea · Motor control enhancement · Trembling · Dizziness · Tingling / electric sensations · Abnormal heartbeat
Pupil dilation · Dehydration sensation · Heart rate perception changes · Muscle tension · Restlessness · Excessive sweating · Body high · Headache · Respiratory stimulation · Sexual arousal enhancement · Bruxism · Tactile euphoria · Breathing alteration · Nausea · Motor control enhancement · Trembling · Dizziness · Tingling / electric sensations
Motivation enhancement · Aesthetic enhancement · Cognitive dysphoria · Immersion enhancement · Information processing enhancement · Motivation suppression · Analysis enhancement · Language enhancement · Thought organization · Novelty enhancement · Pattern recognition enhancement · Creativity enhancement · Memory enhancement
Information processing enhancement · Motivation suppression · Analysis enhancement · Language enhancement · Thought organization · Novelty enhancement · Pattern recognition enhancement · Creativity enhancement · Memory enhancement
Irritability · Anhedonia · Emotional enhancement · Empathy enhancement · Anxiety suppression
Anxiety suppression
Flow state · Ego inflation · Social connection · Self-control enhancement
Timeline
Initial awareness of stimulation emerges — a subtle mood shift and slight restlessness. Effects may be difficult to distinguish from anticipation at first.
Energy builds steadily, focus sharpens, and physical activation increases. Appetite suppression begins and sociability may emerge. Heart rate elevation becomes perceptible.
Full stimulant state — cognitive euphoria, sustained focus enhancement, sociability, and physical energy are at maximum. Cardiovascular activation present. Compulsive redosing urge may surface.
Gradual decline in stimulation with emerging fatigue and irritability. Cognitive performance degrades. Mood may shift toward dysphoria as monoamine stores deplete.
Post-stimulant dysphoria, physical fatigue, depressed mood, and residual insomnia. Appetite may slowly return. Cognitive fatigue and irritability can persist for hours.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 14 days
- Physical
- Low
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- Moderate
- Cross-tol.
- amphetamine · methamphetamine · MDMA
Toxicity
Acute toxicity
3-FMA produces dose-dependent lethality in mice, but no LD₅₀ has been formally calculated for any species.[5] No minimum lethal dose in humans has been established.
Human fatalities associated with 3-FMA have been reported to regulatory bodies in Finland and England/Wales, but no peer-reviewed case reports document the circumstances, doses, or toxicological findings.[6][2]
Cardiovascular toxicity
As a catecholamine releaser, 3-FMA is expected to produce vasoconstriction, rapid heart rate, and elevated blood pressure. Acute risks include dangerously high blood pressure, irregular heartbeat, and reduced blood flow to the heart. Chronic exposure carries risk for heart muscle weakening and elevated lung blood pressure.[13][14]
All cardiovascular claims are inferred from methamphetamine class data — no 3-FMA-specific cardiovascular studies exist.safety citation needed
Hyperthermia
Dangerous overheating is a primary mechanism of acute amphetamine-class toxicity and was directly demonstrated in 3-FMA-treated mice.[5] Hot environments and physical exertion compound this risk.
Neurotoxicity
At high doses, 3-FMA triggers a cascade of brain damage in rodents: massive dopamine release overwhelms cellular defenses, inflammatory immune cells activate, reactive oxygen species accumulate, and nerve cells die.[5] This damage depends on D1 receptor activation — unlike methamphetamine, where D2 receptors play the larger role — which may mean D2-blocking medications do not protect against 3-FMA-induced neurotoxicity.
Psychological Risks
No controlled human data exist for 3-FMA's psychological risk profile. The following risks are inferred from the methamphetamine class and community reports[9][10]:
- Anxiety and paranoia at high doses or during the offset phase
- Post-stimulant crash — depressed mood, fatigue, irritability, and anhedonia during the 6–12 hour aftereffects period
- Compulsive redosing — a prominent feature in community reports, supported by high-effort self-administration behavior in rodents[4]
- Insomnia persisting well beyond the subjective peak, particularly with afternoon or evening dosing
- Psychosis risk with sustained high-dose use or sleep deprivation, by analogy with methamphetaminesafety citation needed
Tolerance and Dependence
Community data report a tolerance half-life of approximately 3–7 days, with full tolerance developing during prolonged repeated use.[10] Cross-tolerance with other monoamine releasers — including amphetamine, methamphetamine, and MDMA — is expected but untested for 3-FMA.
No studies have directly examined 3-FMA withdrawal. The closely related compound 3-fluoroethamphetamine (3-FEA) produced significant withdrawal behavior in mice after seven days of repeated dosing, including hyperactivity and depression-like behavior.[15]
Preclinical evidence for high abuse liability is substantial: conditioned place preference, high-breakpoint self-administration, full substitution for methamphetamine in discrimination tests, and reinstatement of drug-seeking by 3-FMA, methamphetamine, and cocaine.[4][6] This places 3-FMA in the same abuse-liability category as methamphetamine and cocaine in preclinical models.
Drug Interactions
No drug interaction studies specific to 3-FMA have been published. All interactions are inferred from methamphetamine pharmacology.safety citation needed
MAOIs — including prescription inhibitors (phenelzine, tranylcypromine, moclobemide) and plant-derived forms (harmine, harmaline) — represent the highest-severity risk. Combining a monoamine releaser with monoamine oxidase inhibition prevents breakdown of released neurotransmitters, risking fatal serotonin syndrome or dangerously high blood pressure.
SSRIs and SNRIs add serotonergic load, increasing serotonin toxicity risk — particularly relevant if 3-FMA retains meaningful serotonin release activity.
Other stimulants produce additive cardiovascular strain: combined catecholamine release compounds blood vessel constriction, rapid heart rate, and overheating risk. This includes prescription stimulants, cocaine, and high-dose caffeine.
Lithium lowers the seizure threshold in combination with stimulants.
Alcohol masks intoxication signals from both substances, increases cardiovascular strain, and worsens dehydration.
Contraindications
All contraindications are inferred from methamphetamine class pharmacology. No 3-FMA-specific data exist.safety citation needed
Absolute:
- Concurrent MAOI use — risk of serotonin toxicity and dangerously high blood pressure; potentially fatal
- Heart conditions — including high blood pressure, coronary artery disease, irregular heartbeat, and heart failure
- Uncontrolled overactive thyroid — increases sensitivity to catecholamines
Relative:
- Psychiatric conditions — anxiety disorders, psychotic disorders, bipolar disorder (stimulants may trigger mania or psychosis)
- Seizure disorders — amphetamine-class compounds lower seizure threshold
- Liver impairment — may slow metabolism, increasing drug exposure
- CYP2D6 poor metabolizer status — elevated exposure and toxicity risk[12]
- Pregnancy and lactation — stimulant exposure risks blood vessel constriction affecting placental blood flowsafety citation needed
Harm Reduction[edit]
Forms & Identification
3-FMA circulates as a white to off-white powder or crystalline solid, visually indistinguishable from dozens of other stimulant research chemicals. This makes reagent testing and analytical verification essential — visual inspection and taste are meaningless indicators of identity or purity.
The most important testing consideration for 3-FMA is confirming that the substance is not a more dangerous isomer or an entirely different compound. Fluorinated amphetamines are structurally similar across positional isomers, and vendor mislabeling has been documented in the research chemical market.
Guidelines
- Test every batch — use reagent kits to verify identity and fentanyl test strips to rule out contamination
- Weigh every dose — use a milligram-precision scale (0.001 g); never estimate powder doses by eye
- Start low — begin at the lower end of reported dose ranges and wait the full onset period (up to 60 minutes oral) before considering a supplement
- Avoid redosing — compulsive redosing is a consistently reported feature; set a firm dose limit before administration and remove remaining material from reach
- Stay hydrated — drink water regularly but avoid overhydration; 250 mL per hour of activity is a reasonable target
- Monitor temperature — move to a cool environment immediately if you feel overheated; hot settings and physical exertion compound hyperthermia risk
- Plan for the comedown — have food, electrolytes, and a comfortable environment prepared; the offset phase commonly includes dysphoria, fatigue, and irritability
- Inform someone — let a trusted person know what you have taken, the dose, and the time
Set & Setting
3-FMA's functional stimulant profile responds strongly to context. Structured, calm environments channel the stimulation toward focus and productivity; loud, hot, or physically demanding settings amplify cardiovascular strain and overheating risk.[5]
The prolonged aftereffects phase (6–12 hours of residual stimulation) means that timing matters — afternoon or evening dosing commonly produces insomnia lasting well into the following day. Plan for a full 24-hour window from dose to normal sleep.
Aftercare & integration. The 3-FMA comedown is primarily physical and neurochemical rather than psychologically complex. Monoamine depletion drives the characteristic post-stimulant crash: low mood, fatigue, irritability, and difficulty concentrating.
Recovery priorities:
- Sleep — the most important recovery factor; melatonin or a dark, quiet room may help if residual stimulation prevents sleep
- Nutrition — appetite suppression during stimulation often leads to significant caloric deficit; eat a full meal as soon as appetite returns, prioritizing protein and complex carbohydrates
- Hydration and electrolytes — replace fluids and minerals lost during the stimulation period
- Rest period — avoid redosing for a minimum of one week to allow neurotransmitter stores to recover; the 3–7 day tolerance half-life provides a physiological basis for this minimum interval
If low mood, irritability, or anhedonia persist beyond 3–5 days after a single use, this may indicate excessive monoamine depletion and warrants a longer recovery period before any subsequent stimulant use.
Recovery & Support
3-FMA's high abuse liability — confirmed in rodent models at levels comparable to methamphetamine[4] — means that patterns of escalating use should be taken seriously. The compulsive redosing urge reported by users is a behavioral marker that correlates with the high-effort drug-seeking observed in preclinical studies.
Warning signs of problematic use include: increasing dose frequency, difficulty maintaining planned abstinence periods, using 3-FMA to manage the comedown from previous use, and continued use despite negative consequences to sleep, mood, or daily function.
Support resources for stimulant dependence include SAMHSA's National Helpline (1-800-662-4357), SMART Recovery (smartrecovery.org), and local addiction services. Stimulant use disorders respond well to cognitive behavioral approaches and contingency management.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Chest pain, tightness, or pressure
- Seizure or uncontrollable muscle rigidity
- Body temperature hot enough to feel through clothing
- Confusion, loss of consciousness, or inability to respond coherently
- Severe agitation or paranoia with risk of self-harm
Immediate steps:
- 1. Call emergency services immediately if any of the above signs are present
- 2. Move the person to a cool, quiet environment
- 3. Remove excess clothing and apply cool water to skin if overheating is suspected
- 4. Place an unconscious person in the recovery position (on their side, airway clear)
- 5. Do not restrain the person unless there is immediate danger of self-harm or harm to others
- 6. Do not induce vomiting
What to tell the dispatcher:
- The substance taken (3-FMA, a stimulant), the approximate dose, and the time of ingestion
- Current symptoms — especially chest pain, seizure activity, or extreme body temperature
- Good Samaritan laws exist in many jurisdictions to protect people who call for help during a drug emergency
No reversal agent exists for stimulant toxicity. Emergency treatment is supportive: cooling, sedation with benzodiazepines, and cardiovascular monitoring.
Legal Status[edit]
3-FMA occupies a mixed legal position internationally. Several jurisdictions have explicitly scheduled it or captured it under broad structural analog or novel psychoactive substance legislation. In the United States, it is not explicitly listed as a controlled substance, though the Federal Analogue Act (21 USC § 813) may apply when 3-FMA is sold or possessed for human consumption, as it is a structural analog of the Schedule II substance methamphetamine.[2]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| Canada | Schedule I (CDSA) | Controlled as methamphetamine analog since 1996[2] |
| China | Controlled substance | Added to national controlled substance list, October 2015[2] |
| Germany | Controlled under NpSG | Neue-psychoaktive-Stoffe-Gesetz, effective November 2016; covers substituted amphetamine structural family[2] |
| United Kingdom | Psychoactive Substances Act 2016 | Blanket prohibition on supply and production of novel psychoactive substances; possession not explicitly criminalized under PSA[2] |
| United States | Not explicitly scheduled | Federal Analogue Act (21 USC § 813) potentially applicable when intended for human consumptionsafety citation needed |
| Sweden | Classified as hazardous goods | Specific scheduling date not confirmedcitation needed |
| Australia | Likely prohibited | 4-FMA is Schedule 9 (prohibited substance); 3-FMA-specific status not confirmedcitation needed |
The legal landscape for fluorinated methamphetamine analogs remains dynamic. Jurisdictions that rely on specific compound scheduling rather than structural family or blanket novel psychoactive substance legislation may not yet cover 3-FMA explicitly. Users and researchers should verify current local status, as scheduling actions may have occurred after the most recent available sources.
references
- [1] ^abFleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR (2007) New insights into the mechanism of action of amphetamines — Annual Review of Pharmacology and Toxicology PMID:17209801
- [2]
- [3] ^abcRickli A, Hoener MC, Liechti ME (2015) Monoamine transporter and receptor interaction profiles of novel psychoactive substances: para-halogenated amphetamines and pyrovalerone cathinones — European Neuropsychopharmacology doi:10.1016/j.euroneuro.2014.12.012
- [4]
- [5]
- [6] ^abcdAnchondo O, Shetty RA, Gatch MB (2025) Locomotor and discriminative stimulus effects of fluorinated analogs of amphetamine and methamphetamine in mice and rats — Journal of Pharmacology and Experimental Therapeutics doi:10.1016/j.jpet.2025.103617